Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):874-80. doi: 10.1007/s00259-013-2370-6. Epub 2013 Mar 6.

Abstract

Purpose: To assess the relationship between serum thyroglobulin (Tg) levels, Tg doubling time (Tg-DT) and the diagnostic performance of (18)F-FDG PET/CT in detecting recurrences of (131)I-negative differentiated thyroid carcinoma (DTC).

Methods: Included in the present study were 102 patients with DTC. All patients were treated by thyroid ablation (e.g. thyroidectomy and (131)I), and underwent (18)F-FDG PET/CT due to detectable Tg levels and negative conventional imaging. Consecutive serum Tg measurements performed before the (18)F-FDG PET/CT examination were used for Tg-DT calculation. The (18)F-FDG PET/CT results were assessed as true or false after histological and/or clinical follow-up.

Results: Serum Tg levels were higher in patients with a positive (18)F-FDG PET/CT scan (median 6.7 ng/mL, range 0.7-73.6 ng/mL) than in patients with a negative scan (median 1.8 ng/mL, range 0.5-4.9 ng/mL; P < 0.001). In 43 (88 %) of 49 patients with a true-positive (18)F-FDG PET/CT scan, the Tg levels were >5.5 ng/mL, and in 31 (74 %) of 42 patients with a true-negative (18)F-FDG PET/CT scan, the Tg levels were ≤5.5 ng/mL. A Tg-DT of <1 year was found in 46 of 49 patients (94 %) with a true-positive (18)F-FDG PET/CT scan, and 40 of 42 patients (95 %) with a true-negative scan had a stable or increased Tg-DT. Moreover, combining Tg levels and Tg-DT as selection criteria correctly distinguished between patients with a positive and a negative scan (P<0.0001).

Conclusion: The accuracy of (18)F-FDG PET/CT significantly improves when the serum Tg level is above 5.5 ng/mL during levothyroxine treatment or when the Tg-DT is less than 1 year, independent of the absolute value.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Cost-Benefit Analysis
  • Female
  • Fluorodeoxyglucose F18 / pharmacology*
  • Follow-Up Studies
  • Humans
  • Iodine Radioisotopes / pharmacology
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Multimodal Imaging*
  • Neoplasm Metastasis
  • Predictive Value of Tests
  • Radiopharmaceuticals / pharmacology
  • Recurrence
  • Sensitivity and Specificity
  • Thyroglobulin / metabolism*
  • Thyroid Neoplasms / pathology*
  • Thyroxine / pharmacology
  • Time Factors

Substances

  • Iodine Radioisotopes
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Thyroglobulin
  • Thyroxine